Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review - PubMed (original) (raw)
Review
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review
Mitsuhiro Akiyama et al. Autoimmun Rev. 2021 Feb.
Abstract
Objective: We investigated the effectiveness of rituximab (an anti-CD20 monoclonal antibody) in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Methods: We performed a systematic literature review from the inception dates until July 20, 2020 for articles reporting rituximab administration to treat EGPA.
Results: We identified a total of 171 patients; most of the patients had refractory or relapsing disease, whereas 14 patients were newly diagnosed with EGPA. Rituximab was used for induction therapy in all patients and administered as four infusions of 375 mg/m2/week, or two infusions of 1000 mg, given 2 weeks apart. The observation period was 6-36 months after rituximab initiation. The remission rates (defined as a Birmingham Vasculitis Activity Score of 0 along with low dose glucocorticoid) were 36 to 100%. Anti-neutrophil cytoplasmic antibody (ANCA)-positive patients tended to respond better to rituximab than ANCA-negative patients. All studies reported the successful reduction of glucocorticoid dose after rituximab treatment. The median glucocorticoid dose at rituximab initiation was 12.5-60 mg/day, which was successfully reduced to 0-8.5 mg/day after rituximab treatment. Scheduled rituximab maintenance treatment significantly reduced the relapse rates as compared to rituximab administered on demand. No new safety signal was reported.
Conclusion: Rituximab effectively induced and sustained remission and reduced glucocorticoid dose in patients with newly diagnosed or relapsing and refractory EGPA; it also showed potentially greater benefit in ANCA-positive patients than in ANCA-negative patients.
Keywords: Anti-neutrophil cytoplasmic antibody; Churg-Strauss syndrome; Eosinophilic granulomatosis with polyangiitis; Rituximab.
Copyright © 2020. Published by Elsevier B.V.
Similar articles
- Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M, Frede N, Venhoff A, Voll RE, Venhoff N. Thiel J, et al. J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1556-1563. doi: 10.1016/j.jaip.2017.07.027. Epub 2017 Sep 12. J Allergy Clin Immunol Pract. 2017. PMID: 28916432 - Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Thiel J, et al. Arthritis Res Ther. 2013 Sep 24;15(5):R133. doi: 10.1186/ar4313. Arthritis Res Ther. 2013. PMID: 24286362 Free PMC article. - Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, Smith R, Sivasothy P, Guillevin L, Merkel PA, Jayne DR. Mohammad AJ, et al. Ann Rheum Dis. 2016 Feb;75(2):396-401. doi: 10.1136/annrheumdis-2014-206095. Epub 2014 Dec 2. Ann Rheum Dis. 2016. PMID: 25467294 - Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
Mutoh T, Shirai T, Sato H, Fujii H, Ishii T, Harigae H. Mutoh T, et al. Rheumatol Int. 2022 Nov;42(11):2069-2076. doi: 10.1007/s00296-021-04950-z. Epub 2021 Jul 21. Rheumatol Int. 2022. PMID: 34287685 Review. - Novel Therapies for ANCA-associated Vasculitis.
Monti S, Brandolino F, Milanesi A, Xoxi B, Delvino P, Montecucco C. Monti S, et al. Curr Rheumatol Rep. 2021 Apr 28;23(6):38. doi: 10.1007/s11926-021-01010-0. Curr Rheumatol Rep. 2021. PMID: 33909172 Review.
Cited by
- Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis.
Ezekwe E, Weskamp AL, Pittman LM, Klion AD. Ezekwe E, et al. Immunol Allergy Clin North Am. 2024 Nov;44(4):629-644. doi: 10.1016/j.iac.2024.07.003. Epub 2024 Aug 16. Immunol Allergy Clin North Am. 2024. PMID: 39389714 Review. - An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis.
Zhou H, Liang W, Hu H, Liu Z, Chu F, Ding G. Zhou H, et al. Clin Exp Immunol. 2024 Oct 16;218(2):120-135. doi: 10.1093/cei/uxae068. Clin Exp Immunol. 2024. PMID: 39139142 Review. - Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment.
Fijolek J, Radzikowska E. Fijolek J, et al. Front Med (Lausanne). 2023 May 3;10:1145257. doi: 10.3389/fmed.2023.1145257. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37215720 Free PMC article. Review. - New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond.
Paroli M, Gioia C, Accapezzato D. Paroli M, et al. Antibodies (Basel). 2023 Mar 21;12(1):25. doi: 10.3390/antib12010025. Antibodies (Basel). 2023. PMID: 36975372 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical